Dana Investment Advisors Inc. Has $14.37 Million Holdings in Phibro Animal Health Corporation $PAHC

Dana Investment Advisors Inc. decreased its stake in Phibro Animal Health Corporation (NASDAQ:PAHC) by 9.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 355,085 shares of the company’s stock after selling 37,794 shares during the period. Dana Investment Advisors Inc.’s holdings in Phibro Animal Health were worth $14,367,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. EverSource Wealth Advisors LLC boosted its holdings in Phibro Animal Health by 7,671.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after purchasing an additional 2,685 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Phibro Animal Health by 768.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock worth $118,000 after purchasing an additional 4,079 shares during the period. Cornerstone Investment Partners LLC acquired a new position in shares of Phibro Animal Health during the third quarter valued at about $209,000. Balboa Wealth Partners bought a new stake in shares of Phibro Animal Health in the third quarter valued at about $216,000. Finally, Jupiter Asset Management Ltd. acquired a new stake in Phibro Animal Health during the third quarter worth about $228,000. Institutional investors own 99.34% of the company’s stock.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 110,842 shares of the business’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $48.38, for a total value of $5,362,535.96. Following the transaction, the chief executive officer directly owned 122,958 shares in the company, valued at $5,948,708.04. The trade was a 47.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders have sold 293,920 shares of company stock worth $13,885,755. Company insiders own 50.13% of the company’s stock.

Phibro Animal Health Price Performance

Phibro Animal Health stock opened at $51.52 on Tuesday. The business has a 50 day simple moving average of $42.66 and a 200 day simple moving average of $40.31. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The company has a market capitalization of $2.09 billion, a PE ratio of 22.90, a price-to-earnings-growth ratio of 0.81 and a beta of 0.80. Phibro Animal Health Corporation has a one year low of $16.16 and a one year high of $56.30.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. The firm had revenue of $373.91 million for the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, sell-side analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be given a dividend of $0.12 per share. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.9%. Phibro Animal Health’s dividend payout ratio (DPR) is 21.33%.

Analyst Upgrades and Downgrades

Several research firms have commented on PAHC. Zacks Research cut Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research report on Friday, February 6th. JPMorgan Chase & Co. upped their target price on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Phibro Animal Health has a consensus rating of “Hold” and an average target price of $37.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.